In a large prospective cohort of 335 WHO grade III and IV gliomas, Beiko and colleagues demonstrated that IDH mutant tumors derive a clear overall survival benefit from total resection, including both enhancing and non-enhancing tumor, while IDH wild type tumors do not14. Here, IDH2 is linked to central nervous system cancer.